error fb Gplus IN twitter down-arrow Email Phone Check-Mark padlock circle_arrow minus plus play_btn close Clipboard_Icon Shopping-Cart_Icon Speech_Bubble_Icon Stethoscope_Icon pharmacists menu left-arrow right-arrow facebook search cart
Back to Article Listing Page

Dexcom Continuous Glucose Monitoring Systems to be Temporarily Offered to Hospitals During COVID-19 Emergency

Dexcom announced today that due to the public health crisis of COVID-19 and the need to preserve personal protective equipment and reduce the frequency of hospital staff exposure to the coronavirus, the company is making its Dexcom G6 CGM System temporarily available for remote patient monitoring in the hospital setting. This decision was made based on feedback received from the U.S. Food and Drug Administration (FDA).

 

The in-hospital standard-of-care for glucose monitoring is a fingerstick meter, which requires healthcare providers to draw blood from a patient to get a reading. Dexcom CGM systems use a small, wearable sensor and transmitter to continuously measure and send glucose levels wirelessly to a receiver or compatible smart device.* The system provides real-time glucose data, reduces the need for fingersticks† and offers remote monitoring.‡

 

“We are committed to producing 100,000 sensors over the next few months for hospitals to monitor COVID-19 patients,” said Kevin Sayer, chairman, president and CEO of Dexcom. “Initially, we will focus on responding to the areas of the country most impacted by the coronavirus and will work to fulfill additional hospital requests as soon as possible. We have people working around the clock to meet this added need while ensuring we can continue care for our existing customers without interruption.”

 

This temporary availability of CGM systems for in-patient use or use in the critical care setting is expected to help reduce physical interaction between caregivers and patients with COVID-19, and proactively alert healthcare providers if there is an urgent hyper- or hypoglycemic event. In addition to providing real-time glucose values, Dexcom CGM systems also display the direction and rate of glucose change, empowering healthcare providers to take proactive measures to help keep patient glucose levels in a target range.

 

Dexcom is committed to supporting the at-risk communities impacted by COVID-19, including people with diabetes, who are at higher-risk for COVID-19-related complications.

 

Healthcare facilities interested in using real-time CGM systems to remotely monitor COVID-19 patients can find additional information here.

 

How to order

To request Dexcom CGM for in-hospital use in response to COVID-19, please complete and submit this online request form.

 

 

 

*For a list of compatible devices, visit www.dexcom.com/compatibility.

†If your glucose alerts and readings from the G6 do not match symptoms or expectations, use a blood glucose meter to make diabetes treatment decisions.

‡Separate Follow app required.

Dexcom to Launch Patient Assistance Program for Current U.S. Customers Impacted by COVID-19 Pandemic

Dexcom Continuous Glucose Monitoring Systems to be Temporarily Offered to Hospitals During COVID-19 Emergency

Media Inquiries

James McIntosh

619-884-2118

Investor Relations

Steve Pacelli

Images & Media

Media Kit